New Board Surveys! Four new surveys are up covering a variety of topics. Please share your opinion on the likelihood of an AP534 partnership; whether ridaforolimus will meet its primary endpoint; the possibility of a secondary financing in the next quarter; or if AP534 will meet its endpoint early.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.